Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Recurrent Glioblastoma Multiforme Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00071539
• Other study ID #: IXR-102-22-188
• Status: Completed
• Phase: Phase 2
• First received: October 28, 2003
• Last updated: January 18, 2012
• Start date: October 2003
• Est. completion date: July 2006

Study information

• Verified date: January 2012
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: July 2006
• Est. primary completion date: January 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

The patients must fulfill all the following criteria:

• Previous histologically-confirmed diagnosis of primary GBM (glioma grade 4 at time of first diagnosis).

• Histologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous resection (surgical or biopsy) and radiation therapy.

• Medically capable of undergoing the planned surgical gross total resection and the catheter placement.

• Age = 18.

• Karnofsky Performance Status of = 70%.

• Life expectancy of = 3 months.

• Patients must already be taking or begin taking corticosteroids at a stable dose of 4 mg every 6 hours for at least 72 hours prior to catheter placement.

• Patients must be capable of taking, or already taking, anticonvulsant medication.

• Patients must have read, signed, and dated an informed consent according to ICH-GCP, the local regulatory requirement and the rules followed at each institution.

Exclusion Criteria:

Patients fulfilling any of the following criteria should not be enrolled in the study:

• Previous myelosuppressive chemotherapy within the past 4 weeks of the start of the infusion. Patients who have received more than two chemotherapy regimens (single therapy or combination therapy) are ineligible.

• Any form of brain radiation within 10 weeks of the start of the infusion.

• Previous gamma knife radiosurgery, stereotactic radiosurgery, and/or internal radiotherapy, unless the recurrence/progression is histologically confirmed (fine-needle biopsy).

• Prior intracavitary biologic response modifiers or monoclonal antibodies.

• Uncontrolled seizures.

• Bilateral or multifocal tumors.

• Evidence of cerebral uncal herniation.

• Midline brain shift on MRI scan of > 0.5 cm prior to resection; patients with subfalcine herniation may be enrolled.

• Tumors involving the brainstem or cerebellum.

• Diffuse subependymal or CSF disease.

• Women who are pregnant or breast feeding. All women of child-bearing potential should be excluded unless they have a negative pregnancy test and are using adequate contraceptive measures or are surgically sterile. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing.

• Fertile males not practicing adequate contraception and whose female partners are not using adequate contraceptive protection.

• Prior or concurrent investigational treatment within 30 days of study entry.

• Active infection requiring treatment or having an unexplained febrile illness.

• Systemic diseases or other conditions which may be associated with unacceptable anesthetic/operative risk and/or which would not allow safe completion of this study protocol.

• Prior or concurrent malignancy (curatively treated carcinoma-in-situ or basal cell carcinoma or patients who have been disease free for at least 5 years are eligible).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioblastoma
• Recurrent Glioblastoma Multiforme

Intervention

Drug:
• TP-38
Recombinant chimeric protein
• TP38
recombinant chimeric protein

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Teva Pharmaceutical Industries

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	% patients alive	28 weeks	Yes
Secondary	Time to progression (TTP)	An independent review committee will review MRI scans and will be blinded to the dose each patient received.	28 weeks	No